Nephronophthisis: should we target cysts or fibrosis?

Pediatric Nephrology

Volumn 31, Issue 4, 2016, Pages 545-554

  Slaats, Gisela G ^a   Lilien, Marc R ^b   Giles, Rachel H ^a  

^a F03233 ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cilia; Ciliopathy; Cysts; Fibrosis; Kidney; NPHP; Paclitaxel

Indexed keywords

PACLITAXEL; URINARY TRACT AGENT;

DISEASE COURSE; DRUG EFFECT; DRUG INDICATION; DRUG TARGETING; END STAGE RENAL DISEASE; HUMAN; KIDNEY CYST; KIDNEY FIBROSIS; NEPHRONOPHTHISIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CILIOPATHIES; COMPLICATION; DRUG EFFECTS; FIBROSIS; KIDNEY; KIDNEY DISEASES, CYSTIC; KIDNEY FAILURE, CHRONIC; METABOLISM; MICROTUBULE; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CILIOPATHIES; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES, CYSTIC; KIDNEY FAILURE, CHRONIC; MICROTUBULES; PACLITAXEL; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UROLOGICAL AGENTS;

EID: 84959510999     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3162-y     Document Type: Review

References (97)

1. Fanconi G, Hanhart E, Von AA, Uhlinger E, Dolivo G, Prader A (1951) Familial, juvenile nephronophthisis (idiopathic parenchymal contracted kidney). Helv Paediatr Acta 6:1–49
2. Hildebrandt F, Zhou W (2007) Nephronophthisis-associated ciliopathies. J Am Soc Nephrol 18:1855–1871
3. Otto EA, Ramaswami G, Janssen S, Chaki M, Allen SJ, Zhou W, Airik R, Hurd TW, Ghosh AK, Wolf MT, Hoppe B, Neuhaus TJ, Bockenhauer D, Milford DV, Soliman NA, Antignac C, Saunier S, Johnson CA, Hildebrandt F, GPN Study Group (2011) Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. J Med Genet 48:105–116
4. Sang L, Miller JJ, Corbit KC, Giles RH, Brauer MJ, Otto EA, Baye LM, Wen X, Scales SJ, Kwong M, Huntzicker EG, Sfakianos MK, Sandoval W, Bazan JF, Kulkarni P, Garcia-Gonzalo FR, Seol AD, O’Toole JF, Held S, Reutter HM, Lane WS, Rafiq MA, Noor A, Ansar M, Devi AR, Sheffield VC, Slusarski DC, Vincent JB, Doherty DA, Hildebrandt F, Reiter JF, Jackson PK (2011) Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. Cell 145:513–528
5. Hildebrandt F, Benzing T, Katsanis N (2011) Ciliopathies. N Engl J Med 364:1533–1543
6. Ala-Mello S, Koskimies O, Rapola J, Kaariainen H (1999) Nephronophthisis in Finland: epidemiology and comparison of genetically classified subgroups. Eur J Hum Genet 7:205–211
7. Hildebrandt F, Waldherr R, Kutt R, Brandis M (1992) The nephronophthisis complex: clinical and genetic aspects. Clin Invest 70:802–808
8. Hamiwka LA, Midgley JP, Wade AW, Martz KL, Grisaru S (2008) Outcomes of kidney transplantation in children with nephronophthisis: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry. Pediatr Transplant 12:878–882
9. Groothoff JW, Cransberg K, Offringa M, van de Kar NJ, Lilien MR, Davin JC, Heymans HS, Dutch cohort study (2004) Long-term follow-up of renal transplantation in children: a Dutch cohort study. Transplantation 78:453–460
10. Pan J, Seeger-Nukpezah T, Golemis EA (2013) The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci 70:1849–1874
11. Fischer E, Legue E, Doyen A, Nato F, Nicolas JF, Torres V, Yaniv M, Pontoglio M (2006) Defective planar cell polarity in polycystic kidney disease. Nat Genet 38:21–23
12. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444:949–952
13. Bukanov NO, Moreno SE, Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O (2012) CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 11:4040–4046
14. Choi HJ, Lin JR, Vannier JB, Slaats GG, Kile AC, Paulsen RD, Manning DK, Beier DR, Giles RH, Boulton SJ, Cimprich KA (2013) NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Mol Cell 51:423–439
15. Ravichandran K, Zafar I, Ozkok A, Edelstein CL (2015) An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant 30:45–53
16. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM (2008) Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 19:1659–1662
17. Ricker JL, Mata JE, Iversen PL, Gattone VH (2002) c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 61[Suppl 1]:S125–S131
18. Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300:F1193–F1202
19. Zhou H, Gao J, Zhou L, Li X, Li W, Li X, Xia Y, Yang B (2012) Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Renal Physiol 302:F1234–F1242
20. Cao Y, Semanchik N, Lee SH, Somlo S, Barbano PE, Coifman R, Sun Z (2009) Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci USA 106:21819–21824
21. Boertien WE, Meijer E, de Jong PE, Ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT (2015) Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Am J Kidney Dis 65:833–841
22. Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT (2013) Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 84:1278–1286
23. Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S (2015) The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. doi:10.1007/s10157-015-1086-2
24. Attanasio M, Uhlenhaut NH, Sousa VH, O’Toole JF, Otto E, Anlag K, Klugmann C, Treier AC, Helou J, Sayer JA, Seelow D, Nurnberg G, Becker C, Chudley AE, Nurnberg P, Hildebrandt F, Treier M (2007) Loss of GLIS2 causes nephronophthisis in humans and mice by increased apoptosis and fibrosis. Nat Genet 39:1018–1024
25. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040
26. Slaats GG, Giles RH (2015) Are renal ciliopathies (replication) stressed out? Trends Cell Biol 25:317–319
27. Simonson MS (2007) Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 71:846–854
28. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ (2015) Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat Rev Nephrol 11:233–244
29. Liu Y (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15:1–12
30. Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T (2013) Snail and Slug, key regulators of TGF-beta-induced EMT, are sufficient for the induction of single-cell invasion. Biochem Biophys Res Commun 435:58–63
31. Grenda R, Wuhl E, Litwin M, Janas R, Sladowska J, Arbeiter K, Berg U, Caldas-Afonso A, Fischbach M, Mehls O, Sallay P, Schaefer F, ESCAPE Trial group (2007) Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF- beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 22:3487–3494
32. Schnaper HW, Hayashida T, Poncelet AC (2002) It’s a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 13:1126–1128
33. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M (2000) Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58:1885–1892
34. Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B (2007) Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 7:243–248
35. Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Slawinska-Morawska M, Aleksandrowicz-Wrona E, Malgorzewicz S, Rutkowski B (2012) Aliskiren and perindopril reduce the levels of transforming growth factor-beta in patients with non-diabetic kidney disease. Am J Hypertens 25:636–639
36. Group ET, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650
37. Zhang J, Gu C, Noble NA, Border WA, Huang Y (2011) Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. Am J Physiol Renal Physiol 301:F723–F732
38. Kok HM, Falke LL, Goldschmeding R, Nguyen TQ (2014) Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol 10:700–711
39. Falke LL, Goldschmeding R, Nguyen TQ (2014) A perspective on anti-CCN2 therapy for chronic kidney disease. Nephrol Dial Transplant 29[Suppl 1]:i30–i37
40. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K (2004) Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15:1430–1440
41. Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, Lin A, Yeowell D (2011) Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4:4
42. Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, Gong R, Bayliss G, Dworkin LD, Yan H, Zhuang S (2012) Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 23:854–867
43. Chen J, Chen JK, Harris RC (2012) Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury. Kidney Int 82:45–52
44. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME (2005) Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16:363–373
45. Avlan D, Tamer L, Ayaz L, Polat A, Ozturk C, Ozturhan H, Camdeviren H, Aksoyek S (2006) Effects of trapidil on renal ischemia-reperfusion injury. J Pediatr Surg 41:1686–1693
46. Eitner F, Bucher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Backstrom G, Eriksson U, Ostman A, Floege J, Ostendorf T (2008) PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 19:281–289
47. Sugiyama N, Kohno M, Yokoyama T (2012) Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Nephrol Dial Transplant 27:1351–1358
48. Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I, Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B, Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O’Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY, Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomai J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A, Otto EA, Hildebrandt F (2012) Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell 150:533–548
49. Airik R, Slaats GG, Guo Z, Weiss AC, Khan N, Ghosh A, Hurd TW, Bekker-Jensen S, Schroder JM, Elledge SJ, Andersen JS, Kispert A, Castelli M, Boletta A, Giles RH, Hildebrandt F (2014) Renal-retinal ciliopathy gene Sdccag8 regulates DNA damage response signaling. J Am Soc Nephrol 25:2573–2583
50. Slaats GG, Ghosh AK, Falke LL, Le Corre S, Shaltiel IA, van de Hoek G, Klasson TD, Stokman MF, Logister I, Verhaar MC, Goldschmeding R, Nguyen TQ, Drummond IA, Hildebrandt F, Giles RH (2014) Nephronophthisis-associated CEP164 regulates cell cycle progression, apoptosis and epithelial-to-mesenchymal transition. PLoS Genet 10:e1004594
51. Rozycki M, Lodyga M, Lam J, Miranda MZ, Fatyol K, Speight P, Kapus A (2014) The fate of the primary cilium during myofibroblast transition. Mol Biol Cell 25:643–657
52. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196
53. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB (2009) Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 297:F729–F739
54. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, van Grunsven LA, Van den Branden C (2011) Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 22:1863–1875
55. Pang M, Zhuang S (2010) Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 335:266–272
56. Prodromou NV, Thompson CL, Osborn DP, Cogger KF, Ashworth R, Knight MM, Beales PL, Chapple JP (2012) Heat shock induces rapid resorption of primary cilia. J Cell Sci 125:4297–4305
57. Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA (2013) HDAC inhibitors in kidney development and disease. Pediatr Nephrol 28:1909–1921
58. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ (2000) Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5:27–34
59. Piperno G, LeDizet M, Chang XJ (1987) Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104:289–302
60. Woo DD, Miao SY, Pelayo JC, Woolf AS (1994) Taxol inhibits progression of congenital polycystic kidney disease. Nature 368:750–753
61. Woo DD, Tabancay AP Jr, Wang CJ (1997) Microtubule active taxanes inhibit polycystic kidney disease progression in cpk mice. Kidney Int 51:1613–1618
62. Martinez JR, Cowley BD, Gattone VH 2nd, Nagao S, Yamaguchi T, Kaneta S, Takahashi H, Grantham JJ (1997) The effect of paclitaxel on the progression of polycystic kidney disease in rodents. Am J Kidney Dis 29:435–444
63. Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JE (1997) Efficacy of taxol in the orpk mouse model of polycystic kidney disease. Pediatr Nephrol 11:728–733
64. Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, Liu Y, Peng Y, Haruna Y, Kanwar YS (2010) Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 90:436–447
65. Karbalay-Doust S, Noorafshan A, Pourshahid SM (2012) Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey. Korean J Urol 53:360–367
66. Sun L, Zhang D, Liu F, Xiang X, Ling G, Xiao L, Liu Y, Zhu X, Zhan M, Yang Y, Kondeti VK, Kanwar YS (2011) Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol 225:364–377
67. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327
68. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667
69. Donaldson KL, Goolsby GL, Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847–855
70. Vaz P, Macassa E, Jani I, Thome B, Mahagaja E, Madede T, Muando V, Biberfeld G, Anderson S, Blanche S (2011) Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected Mozambican children with antiretroviral drugs and chemotherapy. Pediatr Infect Dis J 30:891–893
71. Blaney SM, Seibel NL, O’Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM (1997) Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group trial. J Clin Oncol 15:1538–1543
72. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, Vassal G, Arditti J, Tellingen OV, Iliadis A, Catalin J (2001) Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 84:604–610
73. Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J, Reaman G, Children’s Oncology Group (2006) Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children’s Oncology Group. Cancer 106:1821–1828
74. Zhang D, Li Y, Liu Y, Xiang X, Dong Z (2013) Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-kappaB activation and cytokine production. J Pharmacol Exp Ther 345:69–75
75. Zhou J, Ouyang X, Cui X, Schoeb TR, Smythies LE, Johnson MR, Guay-Woodford LM, Chapman AB, Mrug M (2010) Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int 78:550–560
76. Zhang D, Yang R, Wang S, Dong Z (2014) Paclitaxel: new uses for an old drug. Drug Des Devel Ther 8:279–284
77. Hanania R, Sun HS, Xu K, Pustylnik S, Jeganathan S, Harrison RE (2012) Classically activated macrophages use stable microtubules for matrix metalloproteinase-9 (MMP-9) secretion. J Biol Chem 287:8468–8483
78. Basten SG, Giles RH (2013) Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. Cilia 2:6
79. Zhang J, Guo WH, Wang YL (2014) Microtubules stabilize cell polarity by localizing rear signals. Proc Natl Acad Sci USA 111:16383–16388
80. Song Y, Brady ST (2015) Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol 25:125–136
81. Chen NX, Moe SM, Eggleston-Gulyas T, Chen X, Hoffmeyer WD, Bacallao RL, Herbert BS, Gattone VH 2nd (2011) Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int 80:612–619
82. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF (2007) Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132:1104–1116
83. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052–1061
84. Gattone VH 2nd, Sinders RM, Hornberger TA, Robling AG (2009) Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 76:178–182
85. Tobin JL, Beales PL (2008) Restoration of renal function in zebrafish models of ciliopathies. Pediatr Nephrol 23:2095–2099
86. Falke LL, van Vuuren SH, Kazazi-Hyseni F, Ramazani F, Nguyen TQ, Veldhuis GJ, Maarseveen EM, Zandstra J, Zuidema J, Duque LF, Steendam R, Popa ER, Kok RJ, Goldschmeding R (2015) Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials 42:151–160
87. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G (2010) Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21:1031–1040
88. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840
89. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820–829
90. Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR (2014) Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol 9:881–888
91. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L (2012) Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 27:3560–3567
92. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103:5466–5471
93. Shillingford JM, Leamon CP, Vlahov IR, Weimbs T (2012) Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 23:1674–1681
94. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN (2013) Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80:574–580
95. Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326
96. Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y (2014) Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 349:258–267
97. Hynes AM, Giles RH, Srivastava S, Eley L, Whitehead J, Danilenko M, Raman S, Slaats GG, Colville JG, Ajzenberg H, Kroes HY, Thelwall PE, Simmons NL, Miles CG, Sayer JA (2014) Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisis. Proc Natl Acad Sci USA 111:9893–9898